Printer Friendly

Bioverativ Celebrates World Hemophilia Day with Stories of Impact of Hemophilia Treatment.

M2 PHARMA-April 20, 2018-Bioverativ Celebrates World Hemophilia Day with Stories of Impact of Hemophilia Treatment

(C)2018 M2 COMMUNICATIONS

- Waltham, Massachusetts-based blood disorders therapeutics developer Bioverativ Inc. (NASDAQ: BIVV) joins the global hemophilia community in recognizing World Hemophilia Day 2018, the company said.

To honor this year's theme, Sharing Knowledge Makes Us Stronger, Bioverativ is sharing the stories of people with hemophilia in the developing world and highlighting the life-changing impact treatment can make.

In 2014, Bioverativ and Swedish Orphan Biovitrum AB pledged to donate up to one billion international units (IUs) of clotting factor over 10 years, including up to 500m IUs to the WFH Humanitarian Aid Program over a period up to five years, to help transform the way hemophilia care is delivered in the developing world.

Since donations began in 2015, more than 15,000 people with hemophilia in 40 countries have already been treated with over 260 million IUs of medicine donated by Bioverativ and Sobi to the WFH Humanitarian Aid Program.

Privately held BioVentrix is focused on developing and commercializing minimally invasive therapies for treating HF. The company has received CE mark certification for its closed-chest Revivent TC TransCatheter Ventricular Enhancement System for plication of scar tissue in post-myocardial infarction, ischemic cardiomyopathy patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:0DEVE
Date:Apr 20, 2018
Words:219
Previous Article:Results of Catabasis Pharmaceuticals Trial of Edasalonexent in Duchenne Muscular Dystrophy to be Presented at American Academy of Neurology 70th...
Next Article:amcure Pre-Clinical Data on AMC303's Anti-tumor and Anti-Metastatic Effects Presented at AACR.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters